ALKS
Alkermes plc.
Alkermes plc. (ALKS) has 15 SEC Form 4 filings (29 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 6, 2026.
The most active filer is EVP R&D, Chief Medical Officer Hopkinson Craig C. with 3 filings. Insiders have net sold $2.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Richard F. Pops
- Employees:1,800
- HQ:Dublin, US
- IPO:1991-07-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.1M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$8.6B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $110K | Jul 6 | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $464K | Jul 1 | SEC ↗ | |
Wright Christopher IFirst filing | Director | Sale | 2,000 | $90K | Jun 13 | SEC ↗ |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $375K | Jun 1 | SEC ↗ | |
Parisi Samuel JosephFirst filing | VP, Finance (Interim PAO) | Sale | 16,217 | $687K | May 29 | SEC ↗ |
Gaffin David JosephFirst filing | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $68K | May 5 | SEC ↗ |
Hopkinson Craig C.First filing | EVP R&D, Chief Medical Officer | Sale | 9,000 | $301K | May 2 | SEC ↗ |
Related companies
Alkermes plc. is in the Healthcare sector.